1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Norethindrone (norethisterone outside US) |
| brand | String | Aygestin (5 mg, Rx); Camila, Errin, Heather, Jolivette, Nor-QD, Ortho Micronor, Sharobel (0.35 mg POPs); component of many COCs |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:Progestins|Progestin (synthetic progestogen)]] • [[:Category:Hormonal_contraceptives|Hormonal contraceptive]] • [[:Category:Sex_hormones|Sex hormone]] |
| mechanism | String | '"`UNIQ--vote-000013EE-QINU`"' Higher-dose Aygestin (5 mg) achieves more reliable ovulation suppression and is used for endometriosis and DUB. POP requires strict daily timing because the 24-hour cervical-mucus effect window is narrower than COC'"`UNIQ--ref-000013EF-QINU`"'. |
| uses | String | '"`UNIQ--vote-000013F0-QINU`"', '"`UNIQ--vote-000013F1-QINU`"', '"`UNIQ--vote-000013F2-QINU`"', '"`UNIQ--vote-000013F3-QINU`"', '"`UNIQ--vote-000013F4-QINU`"' |
| starting_dose | String | POP: 0.35 mg PO daily continuously (no placebo week); high-dose 5 mg Aygestin for amenorrhea/endometriosis 5-10 mg/d |
| preparations | String | 0.35 mg POP tablets; 5 mg tablets (Aygestin); component of COCs and combination HRT |
| fda_max | String | Indication-specific |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral |
| onset | String | Contraception within 48 hours of starting (POP); endometrial effects days |
| duration | String | ~24 hours per dose (strict timing required for POP — within 3-hour window each day) |
| halflife | String | ~8 hours'"`UNIQ--ref-000013F5-QINU`"' |
| bioavailability | String | ~65% (oral)'"`UNIQ--ref-000013F6-QINU`"' |
| pregnancy | String | Contraindicated in known pregnancy (Aygestin); the 0.35 mg POP is not teratogenic and does not need to be discontinued before conception planning.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> |
| legal | String | [[USLegal:Prescription only|Rx-only]] in US (note: norgestrel 0.075 mg POP is now OTC as Opill since 2023, but norethindrone POP remains Rx) |
